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Abstract
Background: Microeconomic evaluations of public health programmes such as immunisation typically only consider
direct health benefits and medical cost savings. Broader economic benefits around childhood development, household
behaviour, and macro-economic indicators are increasingly important, but the evidence linking immunization to such
benefits is unclear.
Methods: A conceptual framework of pathways between immunisation and its proposed broader economic benefits
was developed through expert consultation. Relevant articles were obtained from previous reviews, snowballing, and
expert consultation. Articles were associated with one of the pathways and quality assessed using modified Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) criteria.
Results: We found 20 studies directly relevant to one or more pathways. Evidence of moderate quality from
experimental and observational studies was found for benefits due to immunisation in improved childhood
physical development, educational outcomes, and equity in distribution of health gains. Only modelling
evidence or evidence outside the immunization field supports extrapolating these benefits to household
economic behaviour and macro-economic indicators.
Conclusion: Innovative use of experimental and observational study designs is needed to fill evidence gaps
around key pathways between immunisation and many of its proposed economic benefits.
Keywords: Cost-effectiveness, Health economics, Immunisation, Systematic review, Vaccines
Background
Investment in immunisation programmes in both devel-
oped and developing countries has dramatically increased
over the past two decades [1]. This is partly due to the de-
velopment of new vaccines against major diseases [2], as
well as the growth of new financing mechanisms through
organisations such as Gavi, the Vaccine Alliance, and the
Pan American Health Organization [3]. Spending growth
has, in turn, heightened the importance of rigorous justifi-
cation of the value of investing in immunisation [4]. Micro-
economic evaluations are used to inform decision-making
by national and multinational stakeholders, by comparing
the economic cost of implementing vaccine program in-
frastructure, purchase, and delivery, against the health and
economic benefits of vaccination.
However, many cost-effectiveness studies only consider
direct health benefits and medical cost savings, although
some consider a few wider benefits such as indirect (herd)
protection and care-related productivity gains. However,
economists have argued that improvements in health lead to
economic growth through longer-term mechanisms such as
decreasing fertility, strengthening macroeconomic stability,
and improving educational outcomes [5, 6]. More recently,
this economic theory has been applied to investments in im-
munisation. Bärnighausen et al. [7, 8] suggested that the ben-
efits of immunisation programmes could be divided into
‘narrow’ and ‘broad’ benefits. Gains in health, health care
costs, and care-related productivity typically considered in
microeconomic evaluations were categorised as ‘narrow’
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benefits, while additional benefits not normally incorporated
were categorised as ‘broad’ benefits. Other authors have also
proposed pathways by which investment in improving child
health can reap benefits not captured in many evaluations
[5, 6]. Previous reviews have focused on enumerating and
categorising the proposed benefits, rather than appraising
the strength of evidence behind each of them. Several tax-
onomies describing these putative benefits have been pro-
posed [9, 10], and the literature describing them has
recently been reviewed [10, 11]. However, the degree to
which the claims of broader benefits are evidence-based is
not clear.
To address this gap, we constructed a conceptual frame-
work that captures causal pathways linking vaccines to
their proposed benefits and conducted a rapid review of
the validity and strength of evidence behind each pathway.
Our aim is to inform research into filling knowledge gaps
in this area, as well as to strengthen evidence-based advo-
cacy and decision making about vaccination.
Methods
Analytical framework
Two authors of this report (MJ and RH) facilitated expert
consultations during vaccine meetings convened by the
World Health Organization in Toronto (13–14 July 2011),
Geneva (28–29 June 2012), Sydney (10–11 July 2013), and
Bangkok (24–25 November 2014; see Additional file 1 for
participants). Experts at these meetings were given recent
commentaries on the broader economic impacts of vac-
cines and immunisation programmes, and asked to
propose conceptual frameworks mapping the potential
causal relationships between immunisation and these im-
pacts. Formulating the framework took part in several
stages (1) a wide ranging discussion that was synthesized
in the form of an initial flow diagram that participants
agreed on (Toronto), (2) further expansion of the flow dia-
gram in an open discussion, as well as formulating detailed
descriptions of each benefit category (Geneva), (3) final re-
finement of the pathways (Sydney), and (4) discussion of
preliminary results of the evidence review (Bangkok).
Review
Articles describing evidence about the broader eco-
nomic benefits of vaccination and immunisation pro-
grammes were reviewed. Because the scope of these
benefits is poorly defined, a systematic review broad
enough to encompass all potential benefits would need
to cover almost the entirety of the vaccine literature.
However, several more targeted reviews of such benefits
have recently been conducted. Rather than to repeat
the search process, we opted to identify relevant studies
from four existing reviews [10–13], of which two were
systematic [10, 11]. Further references were identified
by the ‘snowball’ method (identifying relevant studies in
the reference lists of articles already included), and
from the expert consultations described previously.
We only reviewed articles for evidence about causal
pathways to broader economic impacts (B3–D4 in Table 1).
We define causality as meaning: (1) vaccination under a
given set of conditions inevitably produces the relevant
benefits, and (2) without vaccination the given set of condi-
tions on its own does not inevitably produce the relevant
benefits. We did not assess evidence supporting the associ-
ation between vaccination and reduced morbidity/mortal-
ity in vaccine recipients, averted health care expenditure,
or productivity losses directly experienced as a result of ill-
ness episodes. This is because there are numerous trials
and trial-based economic evaluations in the epidemio-
logical (as opposed to economic) literature that were
beyond the scope of the reviews we used, but which
give robust experimental evidence about reductions in
morbidity, mortality, and direct and indirect healthcare
costs as a result of vaccination (see for example [14, 15]).
Similarly, we did not assess the quality of evidence behind
herd immunity following vaccination, since this is again
well-established from a multitude of cluster randomized,
household randomized, observational, and post-licensure
surveillance studies (see for example [16, 17]).
Data collection
A standardized electronic form for data collection and
evaluation of the strength of evidence for each pathway
was developed based on a simplified form of the Cochrane
Systematic Review methodology [18]. The form was pilot
tested using three randomly-selected studies to be
reviewed, and modified further. Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE)
criteria were then used to determine the quality of evi-
dence behind each pathway. Each paper identified was
reviewed, graded for evidence quality, and associated with
a pathway in the overall framework by two independent
reviewers (two of JA, NS, MEP and SS). Conflicting results
in terms of evidence grade or associated pathway were
flagged and resolved by consensus following discussion, or
if remaining unresolved, by a senior reviewer (JY).
Randomized controlled trials were given a default
quality rating of ‘high’. They were downgraded by one
level for any of the following that apply and by two
levels for any factor regarded as severe, up to a max-
imum of three:
 Limitations in the design and implementation of
available studies suggesting high likelihood of bias
 Indirectness of evidence (in relation to population,
intervention, comparator group, or surrogate
outcomes – including hypothetical vaccines or
hypothetical measures of demand in willingness to
pay studies)
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 Unexplained heterogeneity or inconsistency of
results (including problems with subgroup analyses)
 Imprecision of results (no statistical significance at
P <0.1)
 High probability of publication bias (including
industry influence from funding or author conflict of
interest, observational studies with small sample
size, use of data collected automatically or from
registries, or use of data collected for previous
studies)
Observational studies that were methodologically sound
with no obvious bias were regarded as providing ‘high’
quality evidence for the existence of pathways being
Table 1 Detailed descriptions of each proposed benefit of immunisation programmes
Category Definition Outcome measures
A. Health-related benefits to vaccinated individuals
A1. Health gains Reduction in morbidity and mortality Cases averted
Deaths averted
QALYs/DALYs saved
A2. Health care cost savings Reduction in direct cost of health care borne by
the public sector or private individuals
Costs saved by health care provider
Health care costs saved by individuals
B. Productivity-related benefits
B1. Productivity gains related to care Reduction in lost days of work due to caring
for a sick patient
Value of productivity
B2. Productivity gains related to health effects Reduction in lost days of work due to sickness
or death of a sick patient
Friction costs
Potential lifetime earnings
B3. Productivity gains related to non-utility
capabilitiesa
Increased lifetime productivity because of enhanced
capabilities (such as improved cognition and
educational attainment) not easily measured using
utility-based preference measures
Educational outcomes
Cognitive outcomes
Potential lifetime earnings
C. Community or health systems externalities
C1. Ecological effects Health improvements in unvaccinated community
members as a result of ecological effects such as herd
immunity, eradication, and reduced antibiotic usage
Indirect vaccine protection
Prevalence of antibiotic resistance
Future cost of disease control averted
C2. Equity More equal distribution of health outcomes Distribution of health outcomes
C3. Financial and programmatic synergies
and sustainability
Improved financial sustainability as a result of effects
such as synergies with other health care programmes
(e.g. delivery platforms), stimulation of private demand,
and mechanisms to enhance group purchasing power
(e.g. PAHO revolving fund)
Financial benefits
Private demand estimates
C4. Household security Improved financial security of households as a result of
reduced risk of catastrophic expenditure
Actuarial value of security
D. Broader economic indicators
D1. Changes to household behaviour Economic improvements due to changes in household
choices such as fertility and consumption/saving as a
result of improved child health and survival
Productivity
Female labour participation
Household investment
Child dependency ratio
D2. Public sector budget impact Change to an individual’s net transfers to the national
budget over his/her lifetime
Return on investment
Net present value of investment
D3. Short-term macroeconomic impact Changes to national income or production as a result
of short-term exogeneous shocks to the economy
Change in GDP (per capita)
Change in sectoral output
D4. Long-term macroeconomic impact Changes to national income or production as a result
of long-term changes to drivers such as labour supply
and foreign direct investment
Change in GDP (per capita)
aMost cost-effectiveness evaluations focus on maximising individual preference-based measures of health. Capabilities refer to the ability of individuals to function
in particular ways, and offer an alternative way to assess the value of health-altering interventions [46]
DALY, Disability-adjusted life year; GDP, Gross domestic product; PAHO, Pan American Health Organization; QALY, Quality-adjusted life-year
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evaluated if they were able to demonstrate very large ef-
fects, ‘moderate’ quality evidence if the effect sizes were
large, and ‘low’ quality evidence if there were small or no
effects. Observational studies that were not methodologic-
ally sound were by default considered be ‘low’ quality evi-
dence, regardless of effect size.
Most studies reviewed were based around models
rather than traditional epidemiological designs involv-
ing primary data collection. There are no GRADE cri-
teria for quality assessment of modelling studies. In
order to account for the existence of such studies as
part of the evidence base, we expanded the categories
of studies in GRADE to include modelling studies but
kept them in a separate category from empirical stud-
ies. Table 2 below shows the grading system used.
Results
Figure 1 and Table 1, respectively, provide the flow dia-
gram and descriptions of the analytical framework arising
from expert discussions about the broader economic im-
pact of vaccines. Additional file 2 describes the relation-
ship of our framework with previous literature in this area.
After review and screening for duplications, 93 unique
journal articles from the original reviews were included
in the initial study. Of these, 23 were identified as being
exempt from or not appropriate for evidence quality re-
view for reasons such as being commentaries rather than
analyses. Evidence quality grades for the remaining stud-
ies are shown in Table 2; 12 additional studies were
identified via expert consultation. Of these 35 studies,
we identified 20 that were directly relevant to one or
more of the pathways in the framework, the findings of
which are summarized below. Details on the studies
identified are shown in Additional file 3.
Productivity-related benefits
Productivity gains due to non-utility capabilities (physical,
cognitive, and education)
Evidence that immunization improves non-utility cap-
abilities (strength of evidence =moderate experimental/
observational)
No experimental studies were reviewed that directly
provided evidence of the impact of immunization on the
physical development of children via reduced morbidity.
A single observational study by Bloom et al. [19], found
no impact on physical development of adolescent children
in the Philippines from the six recommended childhood
vaccines. Moreover, the evidence quality itself was low,
limited by small final sample size and results that are po-
tentially inconsistent with other results on cognition from
the same study.
One randomised trial of moderate quality by Canning
et al. [20], provided direct evidence of the impact of
maternal tetanus immunization in Matlab, Bangladesh,
on the educational outcomes of children, but found
that the effect was confined to only a subset of the
study population. Evidence from observational studies
was not strong, yet remains suggestive. Four studies
point to the same overall conclusion, but all were
rated low due to lack of direct causal evidence or in-
consistency in the results. Two studies were based in
the same study population in Bangladesh as Canning
et al. [20]. Driessen et al. [21] found that measles
vaccination is positively related to future school en-
rolment. Barham et al. [22] also found a significant
relationship between cognition and exposure to a
combined package of maternal and child health in-
terventions, including, but not restricted to, routine
childhood immunization. In India, Kumar [23] estimated
mixed and potentially inconsistent effects on education
from the Expanded Programme on Immunization. Bloom
et al. [19] found a significant impact on the cognitive
development of adolescent children in the Philippines
(subject to the caveat above).
Evidence that immunization produces productivity gains
via improvements in non-utility capabilities (strength of
evidence =modelling)
By improving human capital in the form of increased
physical, cognitive, and educational skills of children,
immunization may have an impact on future workforce
productivity and hence labour income of households as
well as overall economic growth. In one modelling study,
Bloom et al. [24] proposed a methodology to model
these effects, but no experimental or observational stud-
ies were found with long enough follow-up to measure
such effects.
Table 2 Grading of experimental, observational, and modelling studies according to the quality of evidence they provide to support
causal associations between immunisation and its proposed benefits
Quality of evidence Experimental studies Observational studies Modelling studies or conjecture
High Randomised trials Double-upgraded analytical observational studies
Moderate Downgraded randomized trials Upgraded analytical observational studies
Low Double-downgraded randomized trials Analytical observational studies
Very low Triple-downgraded randomized trials Case series and case reports Modelling studies or conjecture
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Community or health systems externalities
Equity (strength of evidence = moderate experimental/
observational, and modelling)
In Bangladesh, Bishai et al. [25] found that the poverty-
related gradient in under-five mortality is significantly
reduced by measles vaccination, improving health equity
directly. As previously cited, Canning et al. [9] found
that maternal tetanus immunization in Bangladesh im-
proves the educational outcomes of children in lower-
income groups, which could potentially result in lower
future income inequality (although none of the reviewed
studies investigated income-related outcomes).
Two recent modelling studies also addressed the im-
pact of rotavirus immunization programmes on equity.
Rheingans et al. [26] modelled the distribution of po-
tential rotavirus vaccine coverage in 25 Gavi countries
by wealth quintile by extrapolating DPT2 coverage in
Demographic and Health Surveys and found that, while
the greatest potential benefit of rotavirus vaccination in
25 Gavi countries was in the poorest quintiles, existing
rates of vaccination coverage are highly skewed towards the
richest quintiles. Therefore, programmes that add new vac-
cines to existing systems without mechanisms to ensure
equity in uptake may actually exacerbate rather than reduce
existing inequity. Verguet et al. [27] modelled programme
impact and consequences of rotavirus vaccination in India
across different wealth strata, showing that the health
and financial protection benefits of rotavirus would
accrue mainly to the poor.
Financial and programmatic synergies and sustainability
(strength of evidence = modelling)
No observational or experimental studies were found
that provided direct evidence of interaction effects be-
tween immunization and other health interventions on
economic outcomes. However, two modelling studies
have explored the interaction between immunization
and other health interventions from a cost-effectiveness
perspective, showing mixed results. Jeuland et al. [28]
examined combinations of new sanitation technologies
and cholera vaccination and found that the incremental
impact of cholera vaccination is reduced depending on
the extent of a pre-existing improved water supply (al-
though not vice versa). Tan-Torres Edejer et al. [29] ex-
amined measles immunization in South East Asia and
Africa, both singly and as part of a package of nine po-
tential interventions for child health, and found that
combinations of interventions offer additive or near-
additive gains (suggesting few interactions).
Several observational studies [30–32] used contingent
valuation or willingness to pay methods to document sub-
stantial positive household demand for various vaccines,
Fig. 1 A conceptual framework for pathways to the broader economic impact of vaccines. Boxes are shaded in colours corresponding to different
major categories in Table 1
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including HIV, dengue, and oral cholera, suggesting that
households would experience private benefits from their
introduction. However, these studies are limited because
the vaccines examined were hypothetical only. In some
cases, it is not clear that ex ante valuations of vaccines
that did not yet exist would match ex post valuations in a
future context. Further, while they provide evidence that
significant private economic benefits exist to households,
it is not possible to distinguish among the various path-
ways that may contribute to those benefits.
Household financial protection (strength of
evidence = modelling)
Two mechanisms have been proposed by which immu-
nization may reduce household financial vulnerability:
firstly, through overall changes in labour earnings or sav-
ings behaviour, and secondly by reducing the risk from
specific health shocks. None of the reviewed studies
provided direct empirical evidence for either of these
pathways. However, Verguet et al. [27] has proposed a
method of ‘extended cost-effectiveness analysis’ that ex-
plicitly measures the value of the financial benefits of
vaccination that accrue from risk mitigation, and applied it
to a model of rotavirus vaccination in India and Ethiopia.
Broader economic indicators
Changes to household behaviour (strength of
evidence = conjecture)
If labour income rises, all else equal, we expect that house-
holds will be able to increase consumption, savings, and
investment in human capital (such as education). Even in
the absence of evidence for longer-term increases in
labour income due to improved human capital, we would
expect changes in immediate household consumption,
savings, and investment because of increased disposable
income as a result of reduced health expenditure and lost
wages. However, no experimental, observational, or mod-
elling studies were found that directly examine the effect
of immunization on changes to household consumption,
saving, or investment behaviour.
As the risk of childhood mortality and morbidity de-
creases and survival rates increase, households may also
be expected to produce fewer children and invest more in
their health [33]. However, no experimental, observational,
or modelling studies were found that directly examine the
impact of immunization on fertility decisions, and their
consequent impact on households.
Public sector budget impact (strength of
evidence = modelling)
One modelling study [34] considered the impact of the fis-
cal space created by the benefits of immunization by pro-
jecting lifetime net tax changes as a result of vaccination
using an accounting model. However, no study provided
direct primary evidence that immunization would yield
such an impact.
Short-term macroeconomic impact (via mitigation of shocks)
(strength of evidence =modelling)
No empirical studies were found that estimated the effects
of vaccination in mitigating the short-term macroeco-
nomic consequences of an infectious disease outbreak.
However, several modelling studies have examined the im-
pact of vaccination (alongside other policy responses) in
the context of an influenza pandemic. Using a computable
general equilibrium model, Smith et al. [35] estimated
the impact of vaccination during an influenza pandemic
in the United Kingdom, using either a pre-pandemic or a
matched vaccine. They found that both strategies can
substantially reduce the potential macroeconomic impact
of a pandemic regardless of disease severity. Similarly,
Keogh-Brown e al. [36] used a multi-sector single coun-
try computable general equilibrium model to evaluate
the impact of antiviral, vaccination, and combined strat-
egies in the United Kingdom, France, Belgium, and the
Netherlands. They found that both vaccine-only and
combined strategies would be cost-saving in either a mild
or severe pandemic.
Long-term macro-economic impact (via changes in
population health, labour force and productivity)
(strength of evidence = none, but weak observational from
non-vaccine fields)
We found no studies of any kind directly examining the
impact that vaccination may have on long-term macro-
economic indicators such as national income, growth, or
foreign direct investment. However, outside the field of
vaccination, there were several studies examining the re-
lationship between improved health in general and such
indicators. In a longitudinal cross-country study, Alsan
et al. [37] found a positive association between popula-
tion health (in terms of life expectancy) and foreign dir-
ect investment. In addition, four modelling or case
studies [24, 38–40] discuss or illustrate how population
or labour force changes may affect national income and
growth. In other work, Soares [41] proposed a model in
which changes in child mortality and life expectancy
stimulate drops in fertility and rises in educational at-
tainment, hence driving economic growth.
Discussion
We have developed a conceptual framework of the
pathways between vaccines and their proposed benefits,
and assessed the strength of evidence behind each path-
way. Our framework builds on previous lists of benefits
[7, 10, 11], but in addition delineates potential causal re-
lationships and outcome measures that could be used to
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capture each kind of benefit, and assesses the existing
strength of evidence behind each proposed benefit.
We obtained mixed results from this assessment of
the validity and strength of evidence behind conceptual
pathways linking immunization programmes with their
proposed benefits. There is indisputable evidence that
vaccines bring ‘narrow’ benefits related to health out-
comes, health care cost savings, and protection against
productivity losses directly related to the illness episode
at the level of individual vaccinees and at the community
level via herd protection. There is also some limited experi-
mental or at least observational evidence that vaccines
bring wider benefits at the household level in the form of
improved non-utility capabilities and equity in the distribu-
tion of health gains by wealth quintile (although one mod-
elling study cautioned that vaccination could also widen
rather than narrow inequities in health distribution). How-
ever, there is only modelling evidence to support extrapolat-
ing these benefits to meso-level household economic
behaviour (in terms of demand for vaccines, consumption,
savings, and investment), as well as macro-level economic
indicators (such as national income, growth, and foreign in-
vestment) that might logically follow.
To incorporate modelling evidence, we expanded the
traditional GRADE criteria to include a category for such
studies. There was a gradient in the robustness of evidence
from the modelling studies we reviewed due to variation
both in the quality of input data (ranging from experimen-
tal data to observational studies or administrative records
to basing assumptions purely on conjecture that human be-
haviour should follow particular rules) and the way the data
were handled (such as the extent to which associations in
non-experimental designs were assumed to imply caus-
ality, and data were extrapolated to new settings or sit-
uations). However, we did not attempt to assess the
quality of modelling evidence. Although there do exist
some frameworks for assessing the quality of mathem-
atical models in health [42–44], none of these were
found to be suitable for this exercise. We note that the
traditional use of modelling studies is not to provide
evidence for a causal relationship, but instead to as-
sume certain previously established causal relationships
in order to predict future outcomes or explore the
consequences of interventions.
Our objective was to conduct a rapid review of the lit-
erature in order to validate a conceptual framework that
evolved out of a consultative process. Since several sys-
tematic and narrative reviews in the area had previously
been carried out, we opted to conduct a review of existing
reviews with additional expert consultation, rather than a
de novo systematic review. Previous reviews also found
that there were few studies examining many of the poten-
tial broader economic benefits of vaccination [9–11]. The
present study adds to the literature by aggregating the
evidence from several published and unpublished reviews
using different search criteria, categorising the studies based
on a conceptual framework that includes causal pathways
between immunization and broader outcomes, distinguish-
ing between empirical and modelling studies, as well as ex-
plicitly grading the quality of the empirical studies.
One limitation is that we focused on the vaccine-
specific literature only, and did not explore the wider lit-
erature on the relationship between health in general (or
other interventions that improve health) and broader eco-
nomic benefits. Since vaccines improve health, it may be
reasonable to assume that the downstream relationship
between health and its economic benefits also apply to
vaccines. Herein, we have taken a conservative approach
by ignoring any evidence relating to pathways in which
immunization programmes were not the ultimate cause.
Conversely, vaccines are only one component of health
systems that contribute to economic benefits. For in-
stance, recent modelling work found that vaccines only
avert around 27 % of childhood diarrhoea and pneumo-
nia deaths, so remaining mortality reductions come from
other interventions such as nutrition, case management,
and hygiene [45]. The benefits of vaccines themselves
depend on favourable epidemiological, environmental,
socioeconomic, and health systems factors that may re-
quire investment in other interventions in health and
other sectors. Hence, it is important that the attention
on the broader economic benefits of vaccination does
not come at the expense other public health measures.
Ideally, evaluations of vaccination should be considered
alongside these measures rather than individually.
Another limitation is that our framework does not
consider the special benefits of maternal vaccination, in-
cluding improved maternal and child health outcomes
following vaccines such as influenza. Further, our frame-
work has focused on the broader economic benefits of
vaccination. However, the broader economic costs of
vaccination are also of increasing interest to decision
making. These include costs related to addressing ad-
verse effects following immunisation and vaccine hesi-
tancy at a societal level.
The absence of evidence from interventional studies
to support many of the proposed pathways does not
imply evidence for the absence of such relationships.
Many vaccines have proven health and economic bene-
fits and are being routinely used in most countries, so
experimental designs that deny vaccines to a proportion
of participants may be considered unethical. Further-
more, associations between interventions and long-term
economic behaviour at the household or macroeco-
nomic level are expensive and time-consuming to in-
vestigate experimentally. Conditions for well-controlled
‘natural’ experiments are also rare. Hence, the use of
designs that would be considered robust in the medical
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literature may be less common in the economics litera-
ture. Similarly, assumptions about human behaviour
(such as rationality) may be well-accepted in in the
economics literature without the need for empirical
justification, but this is not the case in the medical lit-
erature. This may explain the decrease in availability of
experimental or even observational evidence as we
move from health-related outcomes to economic out-
comes at either the household or the macro-economic
level.
Conclusions
The present study highlights the importance of collect-
ing data about such behaviour wherever possible in
order to strengthen the evidence base behind the poten-
tial broader economic impacts of vaccination. For in-
stance, some of the outcomes for which we did not find
experimental evidence (such as household choices around
consumption and savings) could be routinely incorporated
into clinical effectiveness trials of vaccines or into stand-
ard demographic and health surveys, should suitable data
collection instruments be developed. In the interim, in-
novative analyses of historical observational datasets may
provide evidence that would be considered more robust
than models whose assumptions are not driven by data.
There is a need to design the requisite methods and initi-
ate the relevant studies as soon as possible given the in-
creasing importance of broader economic indicators of
vaccine impact in informing investment decisions about
vaccines.
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